Phase 2 Prostate Cancer Trial, Recruiting NCT06990542 Sponsor: University of California, San Diego Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT06990542
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are at least 18 years old
  • People who have signed and dated a consent form agreeing to take part
  • People who are willing and available to follow all study procedures for the full duration of the trial
  • People who have been diagnosed with prostate adenocarcinoma (a specific type of prostate cancer), confirmed through tissue testing, with a plan to treat it using radiation therapy aimed at curing the cancer
  • People whose cancer can be seen on a prostate MRI scan and/or a specialised nuclear imaging scan (PSMA PET-CT), with biopsy results that match what the scans show
  • People who are capable of causing a pregnancy and who agree to use condoms or other effective contraception with their partner during radiation treatment and for at least 6 months afterward

Who may not be able to join:

  • People who have implants in both hips
  • People who have previously had their prostate surgically removed
  • People who have previously received any treatment for prostate cancer, such as focal therapy (note: people who started hormone therapy within the 90 days before joining the trial may still be considered eligible, as long as compatible scans were done within 4 months before starting that hormone therapy — confirm with trial site)
  • People who have previously had radiation therapy to any area of the body that would need to be treated in this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Tyler Seibert, MD, PhD, University of California, San Diego

Phone: (858) 822-5354

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
9 June 2025
Est. completion
1 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Acute toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov